Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19574253 | 0.85 | LMNA (0.50) | L3MBTL1SLC9A1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL1495500 | 0.80 | ADRB2 (0.44) | L3MBTL1ADRB2HTTP2RX3P2RX2 | |
| SCHEMBL13128971 | 0.73 | ADRB2 (0.46) | ADRB2ALDH1A1LMNAPDE2A | |
| SCHEMBL3650358 | 0.73 | ADRB2 (0.46) | ADRB2ALDH1A1LMNAPDE2A | |
| SCHEMBL13877347 | 0.73 | ADRB2 (0.46) | ADRB2ALDH1A1LMNAPDE2A | |
| SCHEMBL1406184 | 0.72 | L3MBTL1 (0.70) | L3MBTL1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL12545564 | 0.72 | TRPA1 (0.52) | ADRB2ALDH1A1HTTSMN1; SMN2LMNA | |
| SCHEMBL19066296 | 0.71 | CA2 (0.40) | ADRB2ALDH1A1LMNA | |
| SCHEMBL4555817 | 0.71 | ADRB2 (0.34) | L3MBTL1ADRB2 | |
| Hydrochloric Acid SCHEMBL4223637 | 0.71 | ADRB2 (0.44) | ADRB2ALDH1A1LMNAPDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2139334-B1 | 2-CYANOPHENYL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2013-07-03 | — | — | EP | disclosed |
| US-20120149700-A1 | 2-CYANOPHENYL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSTIONS AND USES THEREOF | WEI ZHI-LIANG (US) | 2012-06-14 | — | — | US | disclosed |
| US-8076345-B2 | 2-cyanophenyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine compounds, compositions and uses thereof | EVOTEC AG (DE) | 2011-12-13 | — | — | US | disclosed |
| EP-2139334-A1 | 2-CYANOPHENYL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | Renovis, Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| US-20080275037-A1 | 2-Cyanophenyl fused heterocyclic compounds, and compositions and uses thereof | EVOTEC AG (DE) | 2008-11-06 | — | — | US | disclosed |
| WO-2008130481-A1 | 2-CYANOPHENYL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149700-A1 | 2-CYANOPHENYL FUSED HETEROCYCLIC COMPOUNDS, AND COMPOSTIONS AND USES THEREOF | IL1B, IL1A, CRHR1 | L3MBTL1 1367/4885ADRB2 693/4885SLC9A1 4014/4885 |
| US-20080275037-A1 | 2-Cyanophenyl fused heterocyclic compounds, and compositions and uses thereof | CNR2, CNR1, CBR1 | L3MBTL1 1344/4885ADRB2 347/4885SLC9A1 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.